4-hydroxymethylbiphenyl: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 19186 |
| CHEMBL ID | 332299 |
| SCHEMBL ID | 70274 |
| MeSH ID | M0103861 |
| Synonym |
|---|
| nsc233860 |
| nsc-233860 |
| 4-(hydroxymethyl)biphenyl |
| nsc 233860 |
| (1,1'-biphenyl)-4-methanol |
| 4-phenylbenzyl alcohol |
| 4-hydroxymethylbiphenyl |
| nsc 84169 |
| einecs 222-745-2 |
| 4hmb |
| brn 1937761 |
| p-phenylbenzyl alcohol |
| 3597-91-9 |
| 4-biphenylmethanol |
| nsc84169 |
| nsc-84169 |
| biphenyl-4-methanol, 98% |
| AC-11843 |
| CHEMBL332299 |
| (4-phenylphenyl)methanol |
| inchi=1/c13h12o/c14-10-11-6-8-13(9-7-11)12-4-2-1-3-5-12/h1-9,14h,10h2 |
| axchzlojgkswlv-uhfffaoysa- |
| H0608 |
| biphenyl-4-methanol |
| AKOS000121376 |
| 4-hydroxymethyl-biphenyl |
| A823070 |
| biphenyl-4-ylmethanol |
| unii-gn8bn8xcf5 |
| gn8bn8xcf5 , |
| 4-06-00-04693 (beilstein handbook reference) |
| FT-0617685 |
| [1,1'-biphenyl]-4-ylmethanol |
| SCHEMBL70274 |
| 4-phenylbenzylalcohol |
| 4-phenyl-benzylalcohol |
| biphenyl-4-yl methanol |
| biphenyl-4-yl-methanol |
| 1,1'-biphenyl-4-ylmethanol |
| (4-phenylphenyl)-methanol |
| para-phenylbenzyl alcohol |
| 2-(4'-hydroxymethylphenyl)benzene |
| 4-biphenylylmethanol |
| [1,1'-biphenyl]-4-ylmethanol # |
| [1,1'-biphenyl]-4-methanol |
| DTXSID5075234 |
| mfcd00004660 |
| J-519855 |
| F0001-1033 |
| CS-0011723 |
| SY004522 |
| AS-40009 |
| Q63391957 |
| EN300-21124 |
| AMY36651 |
| hydroxymethylbiphenyl, 4- |
| (1,1'-biphenyl-4-yl)methanol |
| Z104492482 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID89369 | Transthyretin (TTR) amyloidogenesis inhibition activity by employing an acid-mediated (pH 4.4) WTTTR amyloid fibril formation assay, at 7.2 uM conc. | 2004 | Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2 | Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.17) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 52 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||